NeuroMax steps up testing of its drug for diabetes complications

NeuroMax, a Russian biotech company, has announced the 1b phase of clinical trials for its brand new drug candidate for pathogenetic treatment of diabetic neuropathy.

NeuroMax, a Russian biotech company, announced late last week that it has launched the 1b phase of clinical trials for its NM-IA-001 (designated BNV-222 internationally), a brand new drug candidate for pathogenic treatment of one of diabetes? most debilitating and frequent complications?diabetic neuropathy. The trial testing stage will last about three months at clinics in Moscow and Yaroslavl some 270km north-east of Moscow. The researchers will use what is known in medicine as double-blind placebo-controlled randomized study to look into the NM-IA-001?s safety and pharmacokinetics when administered in the 150 and 300mg doses in diabetic neuropathy patients. The developer underscored that at the moment, the global market for drugs to fight diabetes complications has little or no products for pathogenic therapy. The future NM-IA-001 (BNV-222) drug may be one of such rare products. The drug candidate, being developed in close partnership with BioNevia Pharmaceuticals Inc., a U.S.-based biotech firm, is a low-molecule inhibitor of aldose reductase, an enzyme, and is believed to help slow down diabetic neuropathy?s clinical course...